Grants and Contracts Details
The specific aims have not been substantially modified from the original grant application. Briefly, Aim 1 is to test bladder permeability in IC patients using an objective permeability test that we developed. Aim 2 is to test whether increased permeability (if it occurs) is associated with any specific urine markers of IC. For Aim 3, urine specimens and symptom scores were taken before and one month after bladder distention. Aim 3 is to test whether any of the urine markers change after distention, whether any marker changes correlate with symptom relief after distention, and whether any of the pre-distention marker levels can predict good (or poor) symptom relief after distention. Aim 3 also will test whether any of the urine markers associate with other clinical features of IC. Aim 4 will test for associations between the urine markers and the relevant bladder biopsy findings. The urine markers for Aims 2-4 include anti-proliferative factor (APF), epidermal growth factor (EGF), heparin-binding EGF-like growth factor (HB-EGF), methylhistamine (MH), interleukins 6 and 8 (IL-6, IL- 8) and cyclic GMP (cGMP).
|Effective start/end date||12/1/04 → 8/31/06|
- National Institute Diabetes & Digestive & Kidney: $97,530.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.